Shigella multivalent conjugate vaccine

A technology that combines vaccines and Shigella, applied in antibacterial drugs, bacterial antigen components, antibody medical components, etc., can solve the problems of immune interference between antigens, immune interference, etc.

Active Publication Date: 2014-07-23
BEIJING ZHIFEI LVZHU BIOPHARM
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The biggest problem in the development of multivalent vaccines is whether there is immune interference between antigens. It has been reported that there is immune interference between antigens in a vaccine containing 6 components of Staphylococcus aureus

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Shigella multivalent conjugate vaccine
  • Shigella multivalent conjugate vaccine
  • Shigella multivalent conjugate vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Fermentation of Shigella

[0050] Open the Shigella species, inoculate in 2 soytone slant, culture at 35-37°C for 12-24 hours, expand in two 500ml liquid medium, culture at 35-37°C on a shaker for 6-12 hours, Expand the seeds in 10-20L liquid medium, culture on a shaker at 35-37°C for 4-8 hours, inoculate in a fermenter containing 300-500L liquid medium, and cultivate at 35-37°C until the growth reaches the end of logarithmic growth or Stable period, during which the pH was maintained at neutral, Gram staining microscopic examination and pure bacteria experiment. The pollution-free culture is sterilized by adding formaldehyde with a final concentration of 0.5-2%, and the bacteria are separated by a continuous flow centrifuge.

Embodiment 2

[0052] lipopolysaccharide extraction

[0053] Use purified water to suspend the bacteria into a 10% bacterial suspension, add 1:1 to 95% phenol aqueous solution, stir thoroughly at 68°C for 1 hour, centrifuge, separate and harvest the water phase, and add water to the phenol phase to the original volume, Extract at 68°C for 30 minutes, centrifuge, and separate the aqueous phase. Combine the two aqueous phases, add ethanol to a concentration of 25%, supplement some salt ions, centrifuge, and remove the precipitate. Add ethanol to the supernatant to a concentration of 75%, and centrifuge to collect the precipitate. After washing with absolute ethanol and acetone, drain.

Embodiment 3

[0055] O-specific polysaccharide extraction

[0056] Dissolve lipopolysaccharide at a concentration of 1% in 1% glacial acetic acid solution, bathe in boiling water for 60-90 minutes, centrifuge at 60,000-80,000 g for 4 hours, collect the supernatant, freeze-dry, dissolve with purified water, and collect the supernatant by centrifugation. The centrifuged supernatant was purified water as the mobile phase, and was subjected to Sephadex G-25 gel chromatography to collect V 0 The nearby polysaccharide fraction, after lyophilization, is the O-specific polysaccharide.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a Shigella multivalent conjugate vaccine which includes five serotypes, i.e., Shigella dysenteriae I type, Shigella flexneri 2a type, Shigella flexneri 3a type, Shigella flexneri 6 type and Shigella sonnei; the Shigella multivalent conjugate vaccine is prepared by the steps of preparing conjugate stock solutions from specific polysaccharides of the bacteria and carrier protein, and mixing five conjugate stock solutions in a proper proportion. The prepared conjugate vaccine disclosed by the invention is applicable to immunoprophylaxis of Shigella infection.

Description

1. Technical field [0001] The invention relates to a polyvalent Shigella polysaccharide-protein conjugated vaccine preparation, especially containing Shigella flexneri type Ⅰ, Shigella flexneri type 2a, Shigella flexneri type 3a, and Shigella flexneri type 6 , Shigella sonnei 5 serotypes of Shigella multivalent conjugate vaccine. 2. Background technology [0002] Shigella is the pathogenic bacterium that causes bacillary dysentery in humans. It is a common and frequently-occurring disease. It affects 160 million patients worldwide and causes 1.1 million deaths every year. About 80% of the cases occur in Asia. my country is an area with a relatively serious incidence of bacillary dysentery. According to the statistics of epidemic monitoring data, the incidence of bacillary dysentery ranks fourth among the statutory A and B infectious diseases, with more than 200,000 cases per year. Due to the limitation of detection methods and serious underreporting, the actual number of ca...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/116A61P31/04A61K39/112
CPCY02A50/30
Inventor 杜琳朱卫华
Owner BEIJING ZHIFEI LVZHU BIOPHARM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap